Empreendimentos Pague Menos SA operates a pharmacy chain in Brazil. It engaged in the retail trade of medicines, perfumes, personal hygiene, and beauty products. It revenues arises mainly from the sale of medicines, perfumes, and several self-service products to the end consumer.
1981
n/a
LTM Revenue $2.6B
LTM EBITDA $156M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Pague Menos reported last 12-month revenue of $2.6B and EBITDA of $156M.
In the same period, Pague Menos generated $871M in LTM gross profit and $29.9M in net income.
See Pague Menos valuation multiples based on analyst estimatesIn the most recent fiscal year, Pague Menos reported revenue of $2.3B and EBITDA of $175M.
Pague Menos expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Pague Menos valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $2.6B | XXX | $2.3B | XXX | XXX | XXX |
Gross Profit | $871M | XXX | $736M | XXX | XXX | XXX |
Gross Margin | 33% | XXX | 32% | XXX | XXX | XXX |
EBITDA | $156M | XXX | $175M | XXX | XXX | XXX |
EBITDA Margin | 6% | XXX | 8% | XXX | XXX | XXX |
EBIT | $105M | XXX | $104M | XXX | XXX | XXX |
EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
Net Profit | $29.9M | XXX | $18.9M | XXX | XXX | XXX |
Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $232M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pague Menos has current market cap of BRL 2.5B (or $454M), and EV of BRL 5.9B (or $1.1B).
As of October 17, 2025, Pague Menos's stock price is BRL 4 (or $1).
See Pague Menos trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.1B | $454M | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialPague Menos's trades at 0.5x EV/Revenue multiple, and 6.2x EV/EBITDA.
See valuation multiples for Pague Menos and 15K+ public compsAs of October 17, 2025, Pague Menos has market cap of $454M and EV of $1.1B.
Equity research analysts estimate Pague Menos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pague Menos has a P/E ratio of 15.2x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $454M | XXX | $454M | XXX | XXX | XXX |
EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
EV/Revenue | 0.4x | XXX | 0.5x | XXX | XXX | XXX |
EV/EBITDA | 7.0x | XXX | 6.2x | XXX | XXX | XXX |
EV/EBIT | 10.3x | XXX | 10.5x | XXX | XXX | XXX |
EV/Gross Profit | 1.2x | XXX | n/a | XXX | XXX | XXX |
P/E | 15.2x | XXX | 24.1x | XXX | XXX | XXX |
EV/FCF | -27.7x | XXX | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPague Menos's last 12 month revenue growth is 12%
Pague Menos's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Pague Menos's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pague Menos's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pague Menos and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 12% | XXX | 14% | XXX | XXX | XXX |
EBITDA Margin | 6% | XXX | 8% | XXX | XXX | XXX |
EBITDA Growth | 16% | XXX | 5% | XXX | XXX | XXX |
Rule of 40 | 19% | XXX | 19% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Sigma Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
Brasil Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
D1000 Varejo Farma | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pague Menos acquired XXX companies to date.
Last acquisition by Pague Menos was XXXXXXXX, XXXXX XXXXX XXXXXX . Pague Menos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Pague Menos founded? | Pague Menos was founded in 1981. |
Where is Pague Menos headquartered? | Pague Menos is headquartered in Brazil. |
Is Pague Menos publicy listed? | Yes, Pague Menos is a public company listed on BVMF. |
What is the stock symbol of Pague Menos? | Pague Menos trades under PGMN3 ticker. |
When did Pague Menos go public? | Pague Menos went public in 2020. |
Who are competitors of Pague Menos? | Similar companies to Pague Menos include e.g. Sigma Healthcare, MedPlus India, SC Ropharma, Brasil Pharma. |
What is the current market cap of Pague Menos? | Pague Menos's current market cap is $454M |
What is the current revenue of Pague Menos? | Pague Menos's last 12 months revenue is $2.6B. |
What is the current revenue growth of Pague Menos? | Pague Menos revenue growth (NTM/LTM) is 12%. |
What is the current EV/Revenue multiple of Pague Menos? | Current revenue multiple of Pague Menos is 0.4x. |
Is Pague Menos profitable? | Yes, Pague Menos is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Pague Menos? | Pague Menos's last 12 months EBITDA is $156M. |
What is Pague Menos's EBITDA margin? | Pague Menos's last 12 months EBITDA margin is 6%. |
What is the current EV/EBITDA multiple of Pague Menos? | Current EBITDA multiple of Pague Menos is 7.0x. |
What is the current FCF of Pague Menos? | Pague Menos's last 12 months FCF is -$39.3M. |
What is Pague Menos's FCF margin? | Pague Menos's last 12 months FCF margin is -1%. |
What is the current EV/FCF multiple of Pague Menos? | Current FCF multiple of Pague Menos is -27.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.